Daniela Angst

Daniela Angst

Auto-generated profile, based on publicly available information

Daniela Angst

Novartis Biomedical Research

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DADaniela Angst
Daniela Angst
FGFrançois Gessier
François Gessier
PJPhilipp Janser
Philipp Janser
AVAnna Vulpetti
Anna Vulpetti
RWRudolf Wälchli
Rudolf Wälchli
BCBruno Cenni
Bruno Cenni

26 October 2012 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DADaniela Angst
Daniela Angst
PJPhilipp Janser
Philipp Janser
JQJean Quancard
Jean Quancard
PBPeter Buehlmayer
Peter Buehlmayer
FBFrederic Berst
Frederic Berst
BBBirgit Bollbuck
Birgit Bollbuck

20 May 2025 in European Journal of Pharmacology
Verified
Journal Article
Open access
RPRobert Pulz
Robert Pulz
DADaniela Angst
Daniela Angst
BCBruno Cenni
Bruno Cenni
Bruton's tyrosine kinase (BTK) mediates B cell receptor and Fc receptor signaling and is a key regulator of autoimmunity and allergy. A series of novel BTK inhibitors (BTKi) are currently in development for non-oncologic indications with covalent-irreversible (remibrutinib, evobrutinib, tolebrutinib, orelabrutinib), covalent-reversible (rilzabrutinib), and non-covalent reversible (fenebrutinib) binding modes. This study characterizes their in vitro potency and selectivity profiles under the same conditions to minimize assay differences across the different binding modes. Covalent BTKi showed human in vitro blood BTK binding in a time- and concentration-dependent manner with remibrutinib being the most potent and fastest in onset of action. Cellular BTK pathway inhibition was determined in human blood B cells and basophils, and for covalent BTKi correlated well with BTK binding. In contrast to the covalent-irreversible remibrutinib, the non-covalent reversible fenebrutinib showed rapid loss of cellular BTK inhibition after washout. Kinase selectivity was assessed in a binding screen across the human kinome, followed by quantification of binding affinities for a selection of kinases. BTKi ranked in their selectivity as follows (most selective to least): remibrutinib, fenebrutinib, evobrutinib, orelabrutinib, rilzabrutinib and tolebrutinib. These data suggest that next generation BTKi show important differences in their in vitro target binding and selectivity when compared under the same conditions.

10 March 2022 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
CBClaudia Betschart
Claudia Betschart
MFMichael Faller
Michael Faller
FZFlorence Zink
Florence Zink
RHRené Hemmig
René Hemmig
JBJutta Blank
Jutta Blank
TKThomas Knoepfel
Thomas Knoepfel

15 October 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JVJuraj Velcicky
Juraj Velcicky
JLJean-Baptiste Langlois
Jean-Baptiste Langlois
MWMichael Wright
Michael Wright
PJPhilipp Janser
Philipp Janser
DADaniela Angst
Daniela Angst
AMAngela Mackay
Angela Mackay